Home
  Network Programs

    Careers
Contact Us
    About Us   Investors Info     News
   

Our Company
biOasis Technologies Inc. (TSX-V:BTI) is a publically traded biopharmaceutical company focused on developing and commercializing proprietary pharmaceutical products and diagnostic technologies for central nervous system (“CNS”) diseases and disorders. Of particular interest is the creation of therapeutic options for patient management to address the limitations to biodistribution presented by the properties of the blood-brain barrier (“BBB”).

Our Business Strategy
BTI’s business strategy emphasizes out-licensing its technologies to qualified partners, and strategic acquisitions of products and technologies relevant to the diagnosis and management of CNS diseases and disorders.

For more about our current development programs click here




Subscribe to our mailing list


February 13, 2013
biOasis named to 2013 TSX Venture 50®
biOasis Technologies Inc. (TSX:V.BTI) announces it has been named one of the 2013 TSX Venture 50® companies. The 2013 TSX Venture 50® includes the top 10 companies in 5 major industry sectors that have been identified as leaders in providing shareholder value on Canada's junior stock exchange.
Read More... >>
 
Upcoming Events

Loading...

biOasis Technologies Inc. was recognized as a TSX Venture 50® company in 2013. TSX Venture 50 is a trade-mark of TSX Inc. and is used under license.

BTV
Bioasis featured on Business Television